These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 870561)

  • 1. Inflammatory cells in solid murine neoplasms. III. Cytotoxicity mediated in vitro by macrophages recovered from disaggregated regressing Moloney sarcomas.
    Russell SW; Gillespie GY; McIntosh AT
    J Immunol; 1977 May; 118(5):1574-9. PubMed ID: 870561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory cells in solid murine neoplasms. IV. Cytolytic T lymphocytes isolated from regressing or progressing Moloney sarcomas.
    Gillespie GY; Hansen CB; Hoskins RG; Russell SW
    J Immunol; 1977 Aug; 119(2):564-70. PubMed ID: 301897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2.
    Alleva DG; Burger CJ; Elgert KD
    J Immunol; 1994 Aug; 153(4):1674-86. PubMed ID: 8046239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nature, function and distribution of inflammatory cells in regressing and progressing Moloney sarcomas.
    Russell SW; Gillespie GY
    J Reticuloendothel Soc; 1977 Aug; 22(2):159-68. PubMed ID: 72153
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumor sponge implantation: an in vivo method for studying syngeneic, primary antitumor lymphocyte responses.
    Vallera DA; Mentzer SJ; Maizel SE
    Cancer Res; 1982 Feb; 42(2):397-404. PubMed ID: 7055792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and persistence of cytolytic T lymphocytes in regressing or progressing Moloney sarcomas.
    Gillespie GY; Russell SW
    Int J Cancer; 1978 Jan; 21(1):94-99. PubMed ID: 304846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory cells in solid murine neoplasms. II. Cell types found throughout the course of Moloney sarcoma regression or progression.
    Russell SW; Gillespie GY; Hansen CB; Cochrane CG
    Int J Cancer; 1976 Sep; 18(3):331-8. PubMed ID: 1085289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophages isolated from regressing Moloney sarcomas are more cytotoxic than those recovered from progressing sarcomas.
    Russell SW; McIntosh AT
    Nature; 1977 Jul; 268(5615):69-71. PubMed ID: 887150
    [No Abstract]   [Full Text] [Related]  

  • 9. Blocking of cell-mediated immunity to Moloney murine sarcoma virus-transformed cells by lactate dehydrogenase virus-antibody complex.
    McDonald TL
    J Natl Cancer Inst; 1983 Mar; 70(3):493-7. PubMed ID: 6572738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgM antibody-dependent cell-mediated cytotoxicity in the Moloney sarcoma virus system: the involvement of T and B lymphocytes as effector cells.
    Lamon EW; Whitten HD; Skurzak HM; Andersson B; Lidin B
    J Immunol; 1975 Nov; 115(5):1288-94. PubMed ID: 1080777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostaglandin E2 content of regressing and progressing Moloney sarcomas.
    Wechsler SJ; Eurell TE; Russell SW
    J Leukoc Biol; 1986 Aug; 40(2):159-68. PubMed ID: 3461095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IFN-gamma- and cell-to-cell contact-dependent cytotoxicity of allograft-induced macrophages against syngeneic tumor cells and cell lines: an application of allografting to cancer treatment.
    Yoshida R; Yoneda Y; Kuriyama M; Kubota T
    J Immunol; 1999 Jul; 163(1):148-54. PubMed ID: 10384111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-T-cell-mediated cytotoxicity in mice with tumors induced by Moloney murine sarcoma virus (M-MuSV). II. Granulocyte-mediatd cytotoxicity against autochthonous target cells isolated from M-MuSV-induced tumors.
    Becker S; Haskill S
    J Natl Cancer Inst; 1980 Aug; 65(2):469-75. PubMed ID: 6249952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spontaneous tumor regression: possible relationship to in vitro parameters of tumor immunity.
    Hellström KE; Hellström I
    Natl Cancer Inst Monogr; 1976 Nov; 44():131-4. PubMed ID: 193017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunity to tumours of the murine leukaemia-sarcoma virus complex.
    Owen JJ; Seeger RC
    Br J Cancer Suppl; 1973 Aug; 1():26-34. PubMed ID: 4374230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide.
    Mullins DW; Burger CJ; Elgert KD
    J Immunol; 1999 Jun; 162(11):6811-8. PubMed ID: 10352302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T lymphocyte tolerance and early appearance of virus-induced cell surface antigens in Moloney-murine leukemia virus neonatally injected mice.
    Collavo D; Zanovello P; Biasi G; Chieco-Bianchi L
    J Immunol; 1981 Jan; 126(1):187-93. PubMed ID: 6969741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid killing of actinomycin D-treated tumor cells by human mononuclear cells. I. Effectors belong to the monocyte-macrophage lineage.
    Colotta F; Peri G; Villa A; Mantovani A
    J Immunol; 1984 Feb; 132(2):936-44. PubMed ID: 6690624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro demonstration of complement-dependent cytotoxic antibodies to Moloney sarcoma cells.
    Tamerius JD; Hellström I
    J Immunol; 1974 Jun; 112(6):1987-96. PubMed ID: 4825783
    [No Abstract]   [Full Text] [Related]  

  • 20. Recognition of H-2Kb mutant target cells by Moloney virus-specific cytotoxic T lymphocytes from bm13 (H-2Db-mutant) mice. II. Relationship of Kbm3 and Kbm11 in restriction specificities and allodeterminants.
    Stukart MJ; Boes J; Melief CJ
    J Immunol; 1984 Jul; 133(1):28-32. PubMed ID: 6202783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.